Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer

Du, Kevin; Mick, Rosemarie; Busch, Theresa M.; Zhu, Timothy C.; Finlay, Jarod C.; Yu, Guoqiang; Yodh, Arjun G.; Malkowicz, S. Bruce; Smith, Debbie; Whittington, Richard; Stripp, Diana; Hahn, Stephen M.

doi:10.1002/lsm.20341

Cited by 94 publications

(70 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As of today several research groups have focused on treating prostate cancer using IPDT, where optical fibers are implanted into the prostate gland [1][2][3]. The fibers deliver therapeutic light, i.e., light that activates the photosensitizing drug, resulting in the generation of radicals.…”

mentioning

confidence: 99%

In vivo photosensitizer tomography inside the human prostate

2009

View full text Add to dashboard Cite

mentioning

confidence: 99%

In vivo photosensitizer tomography inside the human prostate

2009

View full text Add to dashboard Cite

“…3 Besides, the radius of interaction for singlet oxygen is inferior to 0.2 µm and the half life is short, from 0.03 µs to 0.18 ms, according to the medium, inducing cell damages in close proximity of the activated PS. 4 Owing to the localization of the optical fiber into the tumor tissue, an interstitial PDT (iPDT) can be suggested. Thomas et al Several clinical trials have highlighted the interest of PDT for GBM.…”

Section: Introductionmentioning

confidence: 99%

“…Ultrasmall aguIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma eloïse Thomas 1 ludovic colombeau 2 Mickaël gries 3,4 Thibaut Peterlini 3,4 clélia Mathieu 1 Noémie Thomas 3,4 cédric Boura 3,4 céline Frochot 2 régis Vanderesse 5 François lux 1 Muriel Barberi-heyob 3,4 Olivier Tillement 1…”

unclassified

Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma

Thomas¹,

Colombeau²,

Gries³

et al. 2017

IJN

View full text Add to dashboard Cite

Despite combined treatments, glioblastoma outcome remains poor with frequent local recurrences, indicating that a more efficient and local therapy is needed. In this way, vascular-targeted photodynamic therapy (VTP) could help tumor eradication by destroying its neovessels. In this study, we designed a polysiloxane-based nanoparticle (NP) combining a magnetic resonance imaging (MRI) contrast agent, a photosensitizer (PS) and a new ligand peptide motif (KDKPPR) targeting neuropilin-1 (NRP-1), a receptor overexpressed by angiogenic endothelial cells of the tumor vasculature. This structure achieves the detection of the tumor tissue and its proliferating part by MRI analysis, followed by its treatment by VTP. The photophysical properties of the PS and the peptide affinity for NRP-1 recombinant protein were preserved after the functionalization of NPs. Cellular uptake of NPs by human umbilical vein endothelial cells (HUVEC) was increased twice compared to NPs without the KDKPPR peptide moiety or conjugated with a scramble peptide. NPs induced no cytotoxicity without light exposure but conferred a photocytotoxic effect to cells after photodynamic therapy (PDT). The in vivo selectivity, evaluated using a skinfold chamber model in mice, confirms that the functionalized NPs with KDKPPR peptide moiety were localized in the tumor vessel wall.

show abstract

“…This review is not intended to discuss every detail about DCS; rather it provides a flavor for the DCS method and a snapshot of its recent progress in cancer research. For example, DCS has been utilized in the monitoring of tumor-to-normal flow contrasts 25,30 and early hemodynamic/metabolic responses to chemotherapy 30 in human breast cancers, physiological effects of chemoradiation therapy on human head and neck cancers, 29,53 hemodynamic responses to photodynamic therapy (PDT) in human prostate cancers, 28,51 and efficacies of PDT in murine tumor models. 5,35,[55][56][57] In some of these studies, DCS was combined with NIRS in hybrid instruments for accurately extracting tumor blood flow 21 and for calculating tumor metabolic rate of oxygen consumption (TMRO 2 ) from the measured flow and oxygenation data.…”

Section: Introductionmentioning

confidence: 99%

Near-infrared diffuse correlation spectroscopy in cancer diagnosis and therapy monitoring

2012

J. Biomed. Opt.

View full text Add to dashboard Cite

Abstract. A novel near-infrared (NIR) diffuse correlation spectroscopy (DCS) for tumor blood flow measurement is introduced in this review paper. DCS measures speckle fluctuations of NIR diffuse light in tissue, which are sensitive to the motions of red blood cells. DCS offers several attractive new features for tumor blood flow measurement such as noninvasiveness, portability, high temporal resolution, and relatively large penetration depth. DCS technology has been utilized for continuous measurement of tumor blood flow before, during, and after cancer therapies. In those pilot investigations, DCS hemodynamic measurements add important new variables into the mix for differentiation of benign from malignant tumors and for prediction of treatment outcomes. It is envisaged that with more clinical applications in large patient populations, DCS might emerge as an important method of choice for bedside management of cancer therapy, and it will certainly provide important new information about cancer physiology that may be of use in diagnosis.

show abstract

Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer

Cited by 94 publications

References 55 publications

In vivo photosensitizer tomography inside the human prostate

In vivo photosensitizer tomography inside the human prostate

Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma

Near-infrared diffuse correlation spectroscopy in cancer diagnosis and therapy monitoring

Contact Info

Product

Resources

About